索引超出了数组界限。 文章摘要
|本期目录/Table of Contents|

[1]张静,李荣利,相明飞,等.调节性T细胞在动脉粥样硬化中的作用[J].国际心血管病杂志,2024,06:337-341.
点击复制

调节性T细胞在动脉粥样硬化中的作用(PDF)

《国际心血管病杂志》[ISSN:1006-6977/CN:61-1281/TN]

期数:
2024年06期
页码:
337-341
栏目:
综述
出版日期:
2024-12-10

文章信息/Info

Title:
-
作者:
张静; 李荣利; 相明飞; 董松武
236800 安徽医科大学附属亳州医院检验中心（张静，李荣利，相明飞），心内科（董松武）
Author(s):
-
关键词:
调节性T细胞; 动脉粥样硬化; 炎症; 免疫平衡
Keywords:
-
分类号:
-
DOI:
10.3969/j.issn.1673-6583.2024.06.003
文献标识码:
-
摘要:
调节性T细胞（Treg）是具有免疫抑制功能的CD4＋T细胞亚群，在动脉粥样硬化（AS）中起着诱导炎症消退、调节组织修复信号、免疫平衡和血管重构等作用。该文介绍Treg在AS中的作用机制及靶向治疗进展。
Abstract:
-

参考文献/References

[1] Kuan R, Agrawal DK, Thankam FG. Treg cells in atherosclerosis[J]. Mol Biol Rep, 2021, 48(5):4897-4910.
[2] Saigusa R, Winkels H, Ley K. T cell subsets and functions in atherosclerosis[J]. Nat Rev Cardiol, 2020, 17(7):387-401.
[3] Sakaguchi S, Miyara M, Costantino CM, et al. FOXP3＋regulatory T cells in the human immune system[J]. Nat Rev Immunol, 2010, 10(7):490-500.
[4] Scheinecker C, G?schl L, Bonelli M. Treg cells in health and autoimmune diseases: new insights from single cell analysis[J]. J Autoimmun, 2020, 110:102376.
[5] Bocian K, Kiernozek E, Domaga?a-Kulawik J, et al. Expanding diversity and common goal of regulatory T and B cells. I: origin, phenotype, mechanisms[J]. Arch Immunol Ther Exp (Warsz),
[6] Karakus U, Sahin D, Mittl PRE, et al. Receptor-gated IL-2 delivery by an anti-human IL-2 antibody activates regulatory T cells in three different species[J]. Sci Transl Med, 2020, 12(574):eabb9283.
[7] Kita T, Yamashita T, Sasaki N, et al. Regression of atherosclerosis with anti-CD3 antibody via augmenting a regulatory T-cell response in mice[J]. Cardiovasc Res, 2014, 102(1):107-117.
[8] Mitsuiki N, Schwab C, Grimbacher B. What did we learn from CTLA-4 insufficiency on the human immune system?[J]. Immunol Rev, 2019, 287(1):33-49.
[9] Matsumoto T, Sasaki N, Yamashita T, et al. Overexpression of cytotoxic T-lymphocyte-associated antigen-4 prevents atherosclerosis in mice[J]. Arterioscler Thromb Vasc Biol, 2016, 36(6):1141-1151.
[10] Cortés JR, Sánchez-Díaz R, Bovolenta ER, et al. Maintenance of immune tolerance by Foxp3＋ regulatory T cells requires CD69 expression[J]. J Autoimmun, 2014, 55:51-62.
[11] Tsilingiri K, de la Fuente H, Rela?o M, et al. Oxidized low-density lipoprotein receptor in lymphocytes prevents atherosclerosis and predicts subclinical disease[J]. Circulation, 2019, 139(2):243-255.
[12] Zhuang RL, Meng QS, Ma XX, et al. CD4＋FoxP3＋CD73＋regulatory T cell promotes cardiac healing post-myocardial infarction[J]. Theranostics, 2022, 12(6):2707-2721.
[13] Bai ZX, Liu YJ, Zhao Y, et al. Aspirin ameliorates atherosclerotic immuno-inflammation through regulating the Treg/Th17 axis and CD39-CD73 adenosine signaling via remodeling the gut microbiota in ApoE-/- mice[J]. Int Immunopharmacol, 2023, 120:110296.
[14] Zamani MR, Aslani S, Salmaninejad A, et al. PD-1/PD-L and autoimmunity: a growing relationship[J]. Cell Immunol, 2016, 310:27-41.
[15] Cochain C, Chaudhari SM, Koch M, et al. Programmed cell death-1 deficiency exacerbates T cell activation and atherogenesis despite expansion of regulatory T cells in atherosclerosis-prone mice[J]. PLoS One, 2014, 9(4):e93280.
[16] Li MO, Wan YY, Sanjabi S, et al. Transforming growth factor-β regulation of immune responses[J]. Annu Rev Immunol, 2006, 24:99-146.
[17] Edsfeldt A, Singh P, Matthes F, et al. Transforming growth factor-β2 is associated with atherosclerotic plaque stability and lower risk for cardiovascular events[J]. Cardiovasc Res, 2023, 119(11):2061-2073.
[18] Cipollone F, Fazia M, Mincione G, et al. Increased expression of transforming growth factor-beta1 as a stabilizing factor in human atherosclerotic plaques[J]. Stroke, 2004, 35(10):2253-2257.
[19] Caligiuri G, Rudling M, Ollivier V, et al. Interleukin-10 deficiency increases atherosclerosis, thrombosis, and low-density lipoproteins in apolipoprotein E knockout mice[J]. Mol Med, 2003, 9(1-2):10-17.
[20] Kim M, Sahu A, Hwang Y, et al. Targeted delivery of anti-inflammatory cytokine by nanocarrier reduces atherosclerosis in Apo E-/- mice[J]. Biomaterials, 2020, 226:119550.
[21] Li XY, Fang P, Sun Y, et al. Anti-inflammatory cytokines IL-35 and IL-10 block atherogenic lysophosphatidylcholine-induced, mitochondrial ROS-mediated innate immune activation, but spare innate immune memory signature in endothelial cells[J]. Redox Biol, 2020, 28:101373.
[22] Tao LL, Zhu J, Chen YF, et al. IL-35 improves Treg-mediated immune suppression in atherosclerotic mice[J]. Exp Ther Med, 2016, 12(4):2469-2476.
[23] Xie JJ, Wang J, Tang TT, et al. The Th17/Treg functional imbalance during atherogenesis in ApoE-/- mice[J]. Cytokine, 2010, 49(2):185-193.
[24] Herrero-Fernandez B, Gomez-Bris R, Somovilla-Crespo B, et al. Immunobiology of atherosclerosis: a complex net of interactions[J]. Int J Mol Sci, 2019, 20(21):5293.
[25] Mailer RKW, Gister? A, Polyzos KA, et al. Hypercholesterolemia enhances T cell receptor signaling and increases the regulatory T cell population[J]. Sci Rep, 2017, 7(1):15655.
[26] Amersfoort J, Schaftenaar FH, Douna H, et al. Diet-induced dyslipidemia induces metabolic and migratory adaptations in regulatory T cells[J]. Cardiovasc Res, 2021, 117(5):1309-1324.
[27] Kimura T, Tse K, Sette A, et al. Vaccination to modulate atherosclerosis[J]. Autoimmunity, 2015, 48(3):152-160.
[28] Wigren M, Rattik S, Yao Mattisson I, et al. Lack of ability to present antigens on major histocompatibility complex classⅡ molecules aggravates atherosclerosis in ApoE-/- mice[J]. Circulation, 2019, 139(22):2554-2566.
[29] Kyaw T, Toh BH, Bobik A. Foxp3＋CD4＋ regulatory T-cell subtypes and atherosclerosis[J]. Circ Res, 2016, 119(11):1151-1153.
[30] Butcher MJ, Filipowicz AR, Waseem TC, et al. Atherosclerosis-driven Treg plasticity results in formation of a dysfunctional subset of plastic IFNγ＋ Th1/tregs[J]. Circ Res, 2016, 119(11):1190-1203.
[31] Sharma M, Schlegel MP, Afonso MS, et al. Regulatory T cells license macrophage pro-resolving functions during atherosclerosis regression[J]. Circ Res, 2020, 127(3):335-353.
[32] Nikolouli E, Hardtke-Wolenski M, Hapke M, et al. Alloantigen-induced regulatory T cells generated in presence of vitamin C display enhanced stability of Foxp3 expression and promote skin allograft acceptance[J]. Front Immunol, 2017, 8:748.
[33] Kobiyama K, Saigusa R, Ley K. Vaccination against atherosclerosis[J]. Curr Opin Immunol, 2019, 59:15-24.
[34] Dinh TN, Kyaw TS, Kanellakis P, et al. Cytokine therapy with interleukin-2/anti-interleukin-2 monoclonal antibody complexes expands CD4＋CD25＋Foxp3＋ regulatory T cells and attenuates development and progression of atherosclerosis[J]. Circulation, 2012, 126(10):1256-1266.
[35] Britsch S, Langer H, Duerschmied D, et al. The evolving role of dendritic cells in atherosclerosis[J]. Int J Mol Sci, 2024, 25(4):2450.
[36] Bonacina F, Martini E, Svecla M, et al. Adoptive transfer of CX3CR1 transduced-T regulatory cells improves homing to the atherosclerotic plaques and dampens atherosclerosis progression[J]. Cardiovasc Res, 2021, 117(9):2069-2082.
[37] Meng X, Li WJ, Yang JM, et al. Regulatory T cells prevent plaque disruption in apolipoprotein E-knockout mice[J]. Int J Cardiol, 2013, 168(3):2684-2692.
[38] Feng J, Zhang ZM, Kong W, et al. Regulatory T cells ameliorate hyperhomocysteinaemia-accelerated atherosclerosis in apoE-/-mice[J]. Cardiovasc Res, 2009, 84(1):155-163.

备注/Memo

备注/Memo:
通信作者：董松武，E-mail：dongsongwu@163.com
更新日期/Last Update: 2024-12-10